Join to View Full Profile
4383 Medical DrFl 3San Antonio, TX 78229
Phone+1 210-593-5700
Fax+1 210-593-5992
Dr. Rasco is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Emory University School of MedicineResidency, Internal Medicine, 2003 - 2006
The University of Texas Health Science Center at San AntonioClass of 2003
Certifications & Licensure
TX State Medical License 2008 - 2026
GA State Medical License 2005 - 2009
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors.Russell J Schilder, Drew Rasco, Manish R Sharma
Neoplasia. 2025-03-01 - First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies.Shivaani Kummar, Albiruni Abdul Razak, Scott Laurie, Dylan M Glatt, Sariah Kell
Cancer Research Communications. 2025-01-01 - 6 citationsComprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers.Patricia J Keller, Elizabeth J Adams, Rentian Wu, Alexandre Côté, Shilpi Arora
Cancer Research. 2024-08-01
Journal Articles
- A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in AdvancedKent C Shih, Kyriakos P Papadopoulos, Drew W Rasco, Clinical Cancer Research
Lectures
- A phase I study evaluating COM701 in patients with advanced solid tumors.ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
- A phase I study of a novel MDM2 antagonist APG-115 in patients with advancedASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
- A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combinationASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
Press Mentions
Gossamer Bio Announces Early Encouraging Safety and Biomarker Data from Phase 1/2 Study of GB1275 at American Society of Clinical Oncology 2020 Virtual Scientific ProgramMay 29th, 2020
START & Sarah Cannon Partner to Advance Therapies for Patients with CancerJanuary 16th, 2018
MEDIAN Technologies and START Expand Relationship to Three New Centers in Grand Rapids, MI and Madrid, SpainJune 30th, 2016- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
